Approach to the patient with chronic hepatitis C virus infection

Annals of Internal Medicine

Volumn 136, Issue 10, 2002, Pages 747-757

  Herrine, Steven K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINACEA EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HEPATITIS A VACCINE; HEPATITIS C ANTIBODY; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; PEGINTERFERON ALPHA2B; REBETRON; RIBAVIRIN; SILYMARIN; VIRUS RNA;

ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; BEHAVIOR MODIFICATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIAGNOSTIC TEST; DIET; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; FEVER; FOLLOW UP; HEMOLYTIC ANEMIA; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IRRITABILITY; LIVER BIOPSY; LIVER CIRRHOSIS; MYALGIA; NAUSEA; NONHUMAN; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SCREENING TEST; SERODIAGNOSIS; SIDE EFFECT; SYMPTOMATOLOGY; VIRUS TRANSMISSION;

EID: 0037150107     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-10-200205210-00010     Document Type: Review

References (100)

1. Clinical outcomes after transfusion-associated hepatitis C
2. Evaluation of abnormal liver-enzyme results in asymptomatic patients
3. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C
4. Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs
5. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay. A clinicopachologic study and demonstration of the usefulness of a third-generation assay
6. Hepatitis C virus seroconversion rate in established blood donors
7. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy
8. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology
9. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
10. Factors predictive of a beneficial response to therapy of hepatitis C
11. Variability of hepatitis C virus
12. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: A multicentre study
13. Ultrasound detection of abdominal lymphadenomegaly in subjects with hepatitis C virus infection and persistently normal transaminases: A predictive index of liver histology severity
14. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation
15. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis
16. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis
17. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C
18. Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile
19. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)
20. Epidemiology of hepatitis C virus infection in American veterans
21. Epidemiology of hepatitis C viral infection
22. Transfusion-associated hepatitis not due to viral hepatitis type A or B
23. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis
24. A prospective study of posttransfusion hepatitis. The role of Australia Antigen
25. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors
26. Natural history of hepatitis C
27. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C
28. Residual risk of transfusion-associated hepatitis
29. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland
30. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses
31. Correlates of hepatitis C virus infections among injection drug users
32. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
33. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
34. Epidemiology of hepatitis C in the United States
35. Tattooing as a risk of hepatitis C virus infection
36. Hepatitis C transmission by cosmetic tattooing in women
37. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus
38. Risk of acquiring hepatitis C for health care workers and recommendations for prophylaxis and follow-up after occupational exposure
39. Risk factors for hepatitis C virus infection among health care personnel in a community hospital
40. The epidemiology of acute and chronic hepatitis C
41. Occupational risk for hepatitis C virus infection among New York City dentists
42. Seroprevalence of hepatitis B and hepatitis C among rural emergency medical care personnel
43. Transmission of hepatitis C via blood splash into conjunctiva
44. Hepatitis in patients with end-stage renal disease
45. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: A need for new dialysis strategies
46. A prospective study of hepatitis C viremia in renal allograft recipients
47. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
48. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women
49. ACOG committee opinion. Breastfeeding and the risk of hepatitis C virus transmission. Number 220, August 1999
50. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers
51. Long-term mortality after transfusion-associated non-A, non-B hepatitis
52. Pathogenesis, natural history, treatment, and prevention of hepatitis C
53. 45-Year follow-up of hepatitis C virus infection in healthy young adults
54. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
55. Natural course of chronic hepatitis C
56. Impact of alcohol on the histological and clinical progression of hepatitis C infection
57. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
58. Risk factors in community-acquired chronic hepatitis C virus infection: A case-control study in Italy
59. Sexual transmission of hepatitis C virus infection
60. Transmission of hepatitis C virus infection associated with home infusion therapy fot hemophilia
61. Natural history of liver fibrosis progression in patients with chronic hepatitis C
62. Effect of alcohol consumption on serum hepatitis C vitus RNA and histological lesions in chronic hepatitis C
63. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers
64. Exploring the role of diet in modifying the effect of known disease determinants: Application to risk factors of liver cirrhosis
65. The role of liver biopsy in chronic hepatitis C
66. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
67. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
68. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
69. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
70. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
71. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults
72. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report
73. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
74. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
75. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials
76. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin
77. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C
78. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
79. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
80. Peginterferon alfa-2a in patients with chronic hepatitis C
81. A dose-ranging study of PEG-Intron and ribavirin in chronic hepatitis C - Safety, efficacy, and virologic rationale
82. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
83. Surprisingly small effect of antiviral treatment in patients with hepatitis C
84. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
85. Therapy of chronic hepatitis C
86. A survey of the use of herbal medicine in patients with hepatitis C
87. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments
88. Two cases of hepatitis C treated with herbs and supplements
89. Transmission of hepatitis C by ozone enrichment of autologous blood
90. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
91. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis
92. Prospects for a hepatitis C virus vaccine
93. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus
94. Analogy of human immunodeficiency virus to hepatitis C virus: The human immunodeficiency model
95. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
96. Ribozyme gene therapy for hepatitis C virus infection
97. Serine protease inhibitors in patients with chronic viral hepatitis